MTOR and breast cancer: In summary, our results obtained in models of sensitive breast cancer cell lines, lines with acquired resistance, and lines with primary resistance to trastuzumab, exposed to combination therapy with specific inhibitors of the PI3K/AKT/mTOR signalling pathway plus trastuzumab, suggest that this combination therapy favours the reversal of trastuzumab resistance.